Lenvervimab

N/A

Report date: 2024/11/13 20:00:43

Base Information

Drug NameLenvervimab
Drug Alias NameGC-1102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunostimulantsViral antigens modulatorsHBsAg modulators
TargetsViral antigensHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGC Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGC Biopharma Corp
Active IndicationsN/A
Inactive IndicationsHepatitis B, ChronicHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A